Effectiveness of Momordica charantia L. Capsules on Glycemic Control in Subjects with Prediabetes
Keywords:
bitter melon, prediabetes, type 2 diabetes mellitus, HbA1cAbstract
Objective: This study investigated the effectiveness and safety of Momordica charantia L. capsules (MC) on glycemic control in volunteers with subjects.
Method: A double-blind, randomized controlled trial was conducted, volunteers were randomly assigned to receive either MC or a placebo treatment 2 g/d for six months. Every month, subjects were assessed primary outcomes; fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1C), including liver function and renal function tests by laboratory parameters and adverse drug reactions and secondary outcome, which was newly diagnosed diabetes type 2.
Results: Basic characteristics among 2 groups were not different (MC 2 g/d [n=96] vs placebo [n=97]). The average body mass index of volunteers was 26.24 kg/m2 and 25.99 kg/m2 in MC and placebo groups, respectively. In the sixth month, the FPG level decreased significantly from baseline (p<0.05) in the MC group. However, monthly FPG did not differ between MC and placebo groups (p=0.487). Moreover, HbA1c increased slowly in MC treatment as compared to the placebo group (p=0.035). During the study, there were no cases of DM type 2. One case of asymptomatic hypoglycemia was reported in each group. There were no within-group changes in safety parameters except a significant decrease of high-density lipoprotein (HDL) in the MC group (p=0.014).
Conclusion: Consumption of MC 2 g/day may be beneficial in glycemic control. Further studies are needed to be done on prediabetes with high risks
References
Aekplakorn W, Tantayotai V, Numsangkul S, Tatsato N, Luckanajantachote P, Himathongkam T. Evaluation of a community-based diabetes prevention program in Thailand: A cluster randomized controlled trial. J Prim Care Community Health [Internet]. 2019 Jan 1 [cited 2021 Oct 20];10:2150132719847374. Available from: https://doi.org/10.1177/2150132719847374
Wilson ML. Prediabetes: Beyond the borderline. Nursing Clinics of North America [Internet]. 2017 Dec 1 [cited 2021 Oct 25];52(4):665–77. Available from: https://www.sciencedirect.com/science/article/pii/S0029646517300877
Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: A high-risk state for developing diabetes. Lancet [Internet]. 2012 Jun 16 [cited 2021 Oct 19];379(9833):2279–90. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891203
Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care [Internet]. 2002 Dec 1 [cited 2021 Oct 25];25(12):2165–71. Available from: https://care.diabetesjournals.org/content/25/12/2165
Kamenova P. Therapeutic potential of met–formin in normal glucose tolerant persons with metabolic syndrome. Biotechnology & Biotechnological Equipment [Internet]. 2020 Jan 1 [cited 2021 Oct 19];34(1):30–7. Available from: https://doi.org/10.1080/13102818.2019.1711184
Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, Goldenberg R, et al. Pharmacologic glycemic management of type 2 diabetes in adults. Canadian Journal of Diabetes [Internet]. 2018 Apr 1 [cited 2021 Oct 25];42:S88–103. Available from: https://www.canadianjournalofdiabetes.com/article/S1499-2671(17)30845-6/fulltext
ประกาศคณะกรรมการพัฒนาระบบยาแห่งชาติ เรื่อง บัญชียาหลักแห่งชาติ พ.ศ. 2555 ประกาศ ณ วันที่ 29 มีนาคม พ.ศ. 2555. ราชกิจจานุเบกษา เล่ม 129 ตอนพิเศษ 85ง หน้า 17 (ลงวันที่ 25 พฤษภาคม 2555).
Fuangchan A, Seubnukarn T, Jungpattana–wadee D, Sonthisombat P, Ingkaninan K, Plianbangchang P, et al. Retrospective study on the use of bitter melon for type 2 diabetes at Dansai Crown Prince Hospital, Thailand. Srinagarind Medical Journal [Internet]. 2009 [cited 2021 Oct 19];24(4):332–8. Avai–lable from: https://li01.tci-thaijo.org/index.php/SRIMEDJ/article/view/13043
Punikhom P, Tiyaworanant S, Suriyakrai S. The glucose-lowering effects of the powder of Momordica charantia L. fruits on type 2 diabetic patients. Journal of Thai Traditional and Alternative Medicine [Internet]. 2016 [cited 2021 Oct 25];14(1):46–58. Available from: https://www.tci-thaijo.org/index.php/JTTAM/article/download/101908/78916
Ployluan J. Efficacy of an add-on treatment with Momordica charantia (bitter melon) capsules in patients with type 2 diabetes mellitus. Journal of Thai Traditional and Alternative Medicine [Internet]. 2020 Aug 31 [cited 2021 Oct 20];18(2):313–25. Available from: https://he01.tci-thaijo.org/index.php/JTTAM/article/view/238983
Krawinkel MB, Ludwig C, Swai ME, Yang R, Chun KP, Habicht SD. Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania. Journal of Ethnopharmacology [Internet]. 2018 Apr 24 [cited 2021 Oct 25];216:1–7. Available from: https://www.sciencedirect.com/science/article/pii/S0378874117334840
Singh J, Cumming E, Manoharan G, Kalasz H, Adeghate E. Medicinal chemistry of the anti-diabetic effects of Momordica Charantia: Active constituents and modes of actions. Open Med Chem J [Internet]. 2011 Sep 9 [cited 2021 Oct 25];5:70–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174519
Baby Joseph DJ. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pacific Journal of Tropical Disease [Internet]. 2013 Apr [cited 2021 Oct 20];3(2):93. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027280
Cummings E, Hundal HS, Wackerhage H, Hope M, Belle M, Adeghate E, et al. Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Mol Cell Biochem [Internet]. 2004 Jun 1 [cited 2021 Oct 25];261(1):99–104. Available from: https://doi.org/10.1023/B:MCBI.0000028743.75669.ab
Ahmed I, Adeghate E, Cummings E, Sharma AK, Singh J. Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem [Internet]. 2004 Jun 1 [cited 2021 Oct 25];261(1):63–70. Available from: https://doi.org/10.1023/B:MCBI.0000028738.95518.90
Sridhar MG, Vinayagamoorthi R, Suyambunathan VA, Bobby Z, Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. British Journal of Nutrition [Internet]. 2008 Apr [cited 2021 Oct 25];99(4):806–12. Available from: https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/bitter-gourd-momordica-charantia-improves-insulin-sensitivity-by-increasing-skeletal-muscle-insulinstimulated-irs1-tyrosine-phosphorylation-in-highfatfed-rats/D470BE4EB472C23CAD3626673E8A4230#
Abdollahi M, Abu Bakar MZ, Goh Y, Noordin MM, Rezaeizadeh A. The effects of Momordica charantia on the liver in streptozotocin-induced diabetes in neonatal rats. African Journal of Biotechnology [Internet]. 2010 Aug 2;9:5004–12. Available from: https://www.ajol.info/index.php/ajb/article/view/92121
Ahmad Z, Zamhuri KF, Yaacob A, Siong CH, Selvarajah M, Ismail A, et al. In vitro anti-diabetic activities and chemical analysis of polypeptide-k and oil isolated from seeds of Momordica charantia (bitter gourd). Molecules [Internet]. 2012 Aug [cited 2021 Oct 26];17(8):9631–40. Available from: https://www.mdpi.com/1420-3049/17/8/9631
Uebanso T, Arai H, Taketani Y, Fukaya M, Yamamoto H, Mizuno A, et al. Extracts of Momordica charantia suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo) [Internet]. 2007 Dec;53(6):482–8. Available from: https://pubmed.ncbi.nlm.nih.gov/18202535
Sitasawad SL, Shewade Y, Bhonde R. Role of bittergourd fruit juice in stz-induced diabetic state in vivo and in vitro. J Ethnopharmacol [Internet]. 2000 Nov;73(1–2):71–9. Available from: https://pubmed.ncbi.nlm.nih.gov/11025141
Fuangchan A, Sonthisombat P, Seubnukarn T, Chanouan R, Chotchaisuwat P, Sirigulsatien V, et al. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharmacol [Internet]. 2011 Mar 24 [cited 2021 Oct 20];134(2):422–8. Available from: https://pubmed.ncbi.nlm.nih.gov/21211558
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet [Internet]. 2004 Jan 10;363(9403):157–63. Available from: https://pubmed.ncbi.nlm.nih.gov/14726171
Zhou B. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. Zhonghua Liu Xing Bing Xue Za Zhi [Internet]. 2002 Feb;23(1):5–10. Available from: https://pubmed.ncbi.nlm.nih.gov/12015100
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension [Internet]. 2018 Jun 1 [cited 2021 Oct 20];71(6):e13–115. Available from: https://www.ahajournals.org/doi/10.1161/HYP.0000000000000065
Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes [Internet]. 2015 Mar 15 [cited 2021 Oct 20];6(2):296–303. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360422/
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice [Internet]. 2017 Apr 1 [cited 2021 Oct 20];23:1–87. Available from: https://www.sciencedirect.com/science/article/pii/S1530891X20429593
Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: Evaluation of abnormal liver chemistries. Official journal of the American College of Gastroenterology [Internet]. 2017 Jan [cited 2021 Oct 20];112(1):18–35. Available from: https://journals.lww.com/ajg/Fulltext/2017/01000/ACG_Clinical_Guideline__Evaluation_of_Abnormal.13.aspx
Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, et al. KDOQI US Commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). American Journal of Kidney Diseases [Internet]. 2017 Dec 1 [cited 2021 Oct 20];70(6):737–51. Available from: https://www.sciencedirect.com/science/article/pii/S0272638617308983
American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2019. Diabetes Care [Internet]. 2019 Jan;42(Suppl 1):S13–28. Available from: https://pubmed.ncbi.nlm.nih.gov/30559228
Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care [Internet]. 2012 Nov [cited 2021 Oct 20];35(11):2121–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476912
Tsai C-H, Chen EC-F, Tsay H-S, Huang C. Wild bitter gourd improves metabolic syndrome: A preliminary dietary supplementation trial. Nutr J [Internet]. 2012 Jan 13 [cited 2021 Oct 20];11:4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311063/
Baldwa VS, Bhandari CM, Pangaria A, Goyal RK. Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Upsala Journal of Medical Sciences [Internet]. 1977 Jan 1 [cited 2021 Oct 20];82(1):39–41. Available from: https://doi.org/10.3109/03009737709179057
American Diabetes Association. Obesity management for the treatment of type 2 diabetes: Standards of medical care in diabetes-2021. Diabetes Care [Internet]. 2021 Jan;44(Suppl 1):S100–10. Available from: https://pubmed.ncbi.nlm.nih.gov/33298419
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Health Administration Division, Office of the Permanent Secretary, Ministry of Public Health and The Society of Hospital Pharmacist, Ministry of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ข้อความภายในบทความที่ตีพิมพ์ในวารสารเภสัชกรรมคลินิกทั้งหมด รวมถึงรูปภาพประกอบ ตาราง เป็นลิขสิทธิ์ของกองบริหารการสาธารณสุข สำนักงานปลัดกระทรวงสาธารณสุข และ ชมรมเภสัชกรโรงพยาบาลกระทรวงสาธารณสุข การนำเนื้อหา ข้อความหรือข้อคิดเห็น รูปภาพ ตาราง ของบทความไปจัดพิมพ์เผยแพร่ในรูปแบบต่าง ๆ เพื่อใช้ประโยชน์ในเชิงพาณิชย์ ต้องได้รับอนุญาตจากกองบรรณาธิการวารสารเภสัชกรรมคลินิกอย่างเป็นลายลักษณ์อักษร
กองบริหารการสาธารณสุข สำนักงานปลัดกระทรวงสาธารณสุข และ ชมรมเภสัชกรโรงพยาบาลกระทรวงสาธารณสุข อนุญาตให้สามารถนำไฟล์บทความไปใช้ประโยชน์และเผยแพร่ต่อได้ โดยอยู่ภายใต้เงื่อนไขสัญญาอนุญาตครีเอทีฟคอมมอน (Creative Commons License: CC) โดย ต้องแสดงที่มาจากวารสาร – ไม่ใช้เพื่อการค้า – ห้ามแก้ไขดัดแปลง, Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
ข้อความที่ปรากฏในบทความในวารสารเป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับกองบริหารการสาธารณสุข สำนักงานปลัดกระทรวงสาธารณสุข และ ชมรมเภสัชกรโรงพยาบาลกระทรวงสาธารณสุข และบุคลากรในกองฯ หรือ ชมรมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใด ๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเอง ตลอดจนความรับผิดชอบด้านเนื้อหาและการตรวจร่างบทความเป็นของผู้เขียน ไม่เกี่ยวข้องกับกองบรรณาธิการ
